PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL			Attorney's Docket No: 2836-D
Serial No. 09/448,378	Filing Date Nov. 23, 1999	Examiner P. Gambel	Group Art Unit 1644

In Re Application of Kenneth Brasel et al.

For METHODS OF USING FLT3-LIGAND FOR AUGMENTING AN IMMUNE RESPONSE FOR THE TREATMENT OF CANCER (as amended)

TO THE COMMISSIONER FOR PATENTS:

☒ Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):

- ☐ One month of original due date ($110.00)
- ☐ Two months of original due date ($420.00)
- ☒ Three months of original due date ($950.00)
- ☐ Four months of original due date ($1,480.00)
- ☐ Five months of original due date ($2,010.00)

☒ A response in connection with the matter for which this extension is requested:

- ☒ is filed herewith.
- ☐ has been filed.
- ☐ The response is the filing of a continuing prosecution application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.

☒ The accompanying papers include amended claims for which no additional fee is required.

☐ The accompanying papers include amended claims the fee for which has been calculated as follows:

CLAIMS AS AMENDED

(1)	(2) Claims remaining After amendment	(3)	(4) Highest number Previously paid for	(5) No. of Extra claims present	(6) Rate	(7) Additional Fee
Total Claims		Minus	=	0	x $18	= $ 0.00
Indep. Claims		Minus	=	0	x $86	= 0.00
☐ First Appearance of a multiple dependent claim					+ $290	= 0.00
Total Additional Fee for this Amendment						$0.00

* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.

☐ The following other fees are incurred by the accompanying papers.

- ☐ Other: _____

☒ Please charge Deposit Account No. 09-0089 in the name of Immunex Corporation in the amount of $950 A duplicate copy of this petition is attached.

☒ If an additional extension of time is required, please consider this a request therefore.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 09-0089.

Please Send Future Correspondence To:

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
(206) 265-7000

James E. Klaniecki
Attorney for Applicants)
Registration No.: 38,207
Phone: (206) 265-7145
Date: April 22, 2004

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the dated listed below.

April 22, 2004 _____
Date Signature

04/22/2004 UNUMES 00000001 090089 09448378
01 FC:1253 950.00 DA

RECEIVED
CENTRAL FAX CENTER
APR 22 2004

OFFICIAL

AMGEN®
Amgen Inc.
Law Department
1201 Amgen Court West
Seattle, WA 98119

Telephone: (206) 265-7145
Facsimile: 206-233-0644

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: United States Patent Office FAX: 703-872-9306
ATTN: TC1600

From: James E. Klaniecki Date: April 22, 2004
Corporate Counsel/Patent Attorney
206-265-7000 Ext. 57145

No. of pages including this page: 10

Re: US Patent Application Serial No: 09/448,378
Filed: November 23, 1999
For: METHODS OF USING FLT3-LIGAND FOR AUGMENTING AN IMMUNE RESPONSE FOR THE TREATMENT OF CANCER (AS AMENDED)

The following documents are being facsimile transmitted to the USPTO, ATTN: TC1600:

Amendment Transmittal Letter (1 page) (+ copy);
Amendment and Reply (7 pages)

If transmission problems occur contact Nanci Kertson at 206-587-0430 Ext. 54449.

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.